ROIV Roivant Sciences Ltd

$16.26

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 10/6/2025

About Roivant Sciences Ltd

No Company Description Available

Website: N/A

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
March
CIK
1635088
Address
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11, BM
Valuation
Market Cap
$7.24B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
1.40
Performance
EPS
$-1.00
Dividend Yield
Profit Margin
-95.10%
ROE
-14.60%
Technicals
50D MA
$10.40
200D MA
$11.25
52W High
$13.05
52W Low
$8.73
Fundamentals
Shares Outstanding
714M
Target Price
$16.00
Beta
1.25

ROIV EPS Estimates vs Actual

Estimated
Actual

ROIV News & Sentiment

Sep 23, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. ( ROIV ) is a Great Choice
Does Roivant Sciences Ltd. (ROIV) have what it takes to be a top stock pick for momentum investors? Let's find out.
Sep 18, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Montes Archimedes Acquisition ( ROIV ) Surges 7.8%: Is This an Indication of Further Gains?
Montes Archimedes Acquisition (ROIV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Sep 17, 2025 • Motley Fool BULLISH
Why Roivant Sciences Stock Is Soaring Today
The drugmaker just cleared a major hurdle to winning FDA approval for a promising autoimmune disease drug.
Sep 17, 2025 • Benzinga SOMEWHAT-BULLISH
Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial - Roivant Sciences ( NASDAQ:ROIV )
Brepocitinib 30 mg improved the Total Improvement Score to 46.5 vs 31.2 for placebo at week 52. 42% of brepocitinib patients stopped steroids completely vs 23% for placebo by the end of the study. Up Next: Wall Street trader's 34-0 strategy goes public this week. See it first →
Sep 17, 2025 • Benzinga SOMEWHAT-BULLISH
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday - Robo.ai ( NASDAQ:AIIO ) , Blue Gold ( NASDAQ:BGL )
U.S. stocks were mixed, with the Dow Jones index gaining more than 200 points on Wednesday. Shares of Lyft, Inc. LYFT rose sharply during Wednesday's session after the company and Waymo announced plans to expand to Nashville next year, with Lyft's Flexdrive managing Waymo's fully autonomous ...
Aug 12, 2025 • Motley Fool SOMEWHAT-BULLISH
Why Roivant Sciences Stock Bounced Back on Tuesday
Investors were in a forgiving mood after Monday's dispiriting earnings release.
Sentiment Snapshot

Average Sentiment Score:

0.168
50 articles with scored sentiment

Overall Sentiment:

Bullish

ROIV Reported Earnings

Feb 11, 2025
Dec 31, 2024 (Pre market)
0.04 Surprise
  • Reported EPS: $-0.20
  • Estimate: $-0.24
  • Whisper:
  • Surprise %: 17.2%
Nov 12, 2024
Sep 30, 2024 (Pre market)
-0.05 Surprise
  • Reported EPS: $-0.31
  • Estimate: $-0.26
  • Whisper:
  • Surprise %: -20.4%
Aug 08, 2024
Jun 30, 2024 (Pre market)
0.38 Surprise
  • Reported EPS: $0.12
  • Estimate: $-0.26
  • Whisper:
  • Surprise %: 146.2%
May 30, 2024
Mar 31, 2024 (Pre market)
0.11 Surprise
  • Reported EPS: $-0.19
  • Estimate: $-0.30
  • Whisper:
  • Surprise %: 36.7%
Feb 13, 2024
Dec 31, 2023 (Pre market)
0.02 Surprise
  • Reported EPS: $-0.30
  • Estimate: $-0.32
  • Whisper:
  • Surprise %: 6.2%
Nov 13, 2023
Sep 30, 2023 (Pre market)
-0.09 Surprise
  • Reported EPS: $-0.40
  • Estimate: $-0.31
  • Whisper:
  • Surprise %: -29.0%
Aug 14, 2023
Jun 30, 2023 (Pre market)
-0.08 Surprise
  • Reported EPS: $-0.38
  • Estimate: $-0.30
  • Whisper:
  • Surprise %: -26.7%
Jun 28, 2023
Mar 31, 2023 (Pre market)
0.16 Surprise
  • Reported EPS: $-0.20
  • Estimate: $-0.36
  • Whisper:
  • Surprise %: 44.4%
Feb 13, 2023
Dec 31, 2022 (Pre market)
-0.1 Surprise
  • Reported EPS: $-0.49
  • Estimate: $-0.39
  • Whisper:
  • Surprise %: -25.6%

Financials